+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Smoking Cessation and Nicotine De-Addiction Products Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028

  • Report

  • 100 Pages
  • June 2022
  • Region: Global
  • Infinium Global Research
  • ID: 5626336
The report on the global smoking cessation and nicotine de-addiction products market provides qualitative and quantitative analysis for the period from 2022 to 2028. The report predicts the global smoking cessation and nicotine de-addiction products market to grow with a CAGR of about 15% over the forecast period from 2022-2028. The study on smoking cessation and nicotine de-addiction products market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2022 to 2028.

The report on smoking cessation and nicotine de-addiction products market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global smoking cessation and nicotine de-addiction products market over the period of 2022 to 2028. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global smoking cessation and nicotine de-addiction products market over the period of 2022 to 2028. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings


1) Drivers

  • Growing health consciousness among cigarette smokers
  • Accessibility to a large range of nicotine replacement therapy (NRT) products

2) Restraints

  • High cost associated with smoking cessation products

3) Opportunities

  • New product innovations

Research Methodology


A) Primary Research


The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include:

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

B) Secondary Research


Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered


The global smoking cessation and nicotine de-addiction products market is segmented on the basis of type, and distribution channel.

The Global Smoking Cessation and Nicotine De-addiction Products Market by Type

  • E-cigarettes
  • Drug Therapy
  • Nicotine Replacement Therapies

The Global Smoking Cessation and Nicotine De-addiction Products Market by Distribution Channel

  • Drug Store
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Company Profiles


The companies covered in the report include
  • Takeda Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • NJOY, Inc.
  • Imperial Tobacco Company of India Limited.
  • Cipla Ltd.
  • Revolymer PLC
  • Novartis International AG
  • McNeil AB
  • Glaxo Smith Kline PLC
  • Others

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the smoking cessation and nicotine de-addiction products market.
2. Complete coverage of all the segments in the smoking cessation and nicotine de-addiction products market to analyze the trends, developments in the global market and forecast of market size up to 2028.
3. Comprehensive analysis of the companies operating in the global smoking cessation and nicotine de-addiction products market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Smoking Cessation and Nicotine De-addiction Products Market Highlights
2.2. Smoking Cessation and Nicotine De-addiction Products Market Projection
2.3. Smoking Cessation and Nicotine De-addiction Products Market Regional Highlights
3. Global Smoking Cessation and Nicotine De-addiction Products Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Analysis of COVID-19 impact on the Smoking Cessation and Nicotine De-addiction Products Market
3.4. Porter's Five Forces Analysis
3.5. Growth Matrix Analysis
3.5.1. Growth Matrix Analysis by Type
3.5.2. Growth Matrix Analysis by Distribution Channel
3.5.3. Growth Matrix Analysis by Region
3.6. Value Chain Analysis of Smoking Cessation and Nicotine De-addiction Products Market
4. Smoking Cessation and Nicotine De-addiction Products Market Macro Indicator Analysis
5. The Global Smoking Cessation and Nicotine De-addiction Products Market by Type
5.1. E-cigarettes
5.2. Drug Therapy
5.3. Nicotine Replacement Therapies
6. Global Smoking Cessation and Nicotine De-addiction Products Market by Distribution Channel
6.1. Drug Store
6.2. Retail Pharmacies
6.3. Hospital Pharmacies
6.4. Online Pharmacies
7. Global Smoking Cessation and Nicotine De-addiction Products Market by Region 2022-2028
7.1. North America
7.1.1. North America Smoking Cessation and Nicotine De-addiction Products Market by Type
7.1.2. North America Smoking Cessation and Nicotine De-addiction Products Market by Distribution Channel
7.1.3. North America Smoking Cessation and Nicotine De-addiction Products Market by Country
7.2. Europe
7.2.1. Europe Smoking Cessation and Nicotine De-addiction Products Market by Type
7.2.2. Europe Smoking Cessation and Nicotine De-addiction Products Market by Distribution Channel
7.2.3. Europe Smoking Cessation and Nicotine De-addiction Products Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Smoking Cessation and Nicotine De-addiction Products Market by Type
7.3.2. Asia-Pacific Smoking Cessation and Nicotine De-addiction Products Market by Distribution Channel
7.3.3. Asia-Pacific Smoking Cessation and Nicotine De-addiction Products Market by Country
7.4. RoW
7.4.1. RoW Smoking Cessation and Nicotine De-addiction Products Market by Type
7.4.2. RoW Smoking Cessation and Nicotine De-addiction Products Market by Distribution Channel
7.4.3. RoW Smoking Cessation and Nicotine De-addiction Products Market by Sub-region
8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Smoking Cessation and Nicotine De-addiction Products Market
8.2. Companies Profiled
8.2.1. Takeda Pharmaceutical Co., Ltd.
8.2.2. Pfizer, Inc.
8.2.3. NJOY, Inc.
8.2.4. Imperial Tobacco Company of India Limited.
8.2.5. Cipla Ltd.
8.2.6. Revolymer PLC
8.2.7. Novartis International AG
8.2.8. McNeil AB
8.2.9. Glaxo Smith Kline PLC
8.2.10. Others

Companies Mentioned

  • Takeda Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • NJOY, Inc.
  • Imperial Tobacco Company of India Limited.
  • Cipla Ltd.
  • Revolymer PLC
  • Novartis International AG
  • McNeil AB
  • Glaxo Smith Kline PLC